Technology | January 28, 2015

Maquet Entering Exclusive U.S. Distribution Agreement for TAVR Valvuloplasty Balloon Catheter

Product designed to inflate and deflate rapidly to reduce the duration of blood flow obstruction

Balloon catheters, Heart Valve repair, Cath Lab, Hybrid OR

Image courtesy of InterValve

January 28, 2015 — Maquet Medical Systems USA announced an agreement to serve as the exclusive U.S. distributor of InterValve Inc.'s V8 Aortic Valvuloplasty Balloon Catheter. The V8 catheter is designed to be used in stand-alone balloon aortic valvuloplasty (BAV) and pre-dilatation during transcatheter aortic valve replacement (TAVR) procedures. Maquet's sales representatives in the United States will begin selling the V8 catheter during the first quarter of 2015.

The V8 balloon catheter is designed to inflate and deflate rapidly to reduce the duration of blood flow obstruction across the valve and features a "figure-8" shape balloon that enables the bulbs at either end of the balloon to lock into either side of the aortic annulus. This design has the potential to reduce the risk of balloon movement during dilatation. The V8 is the first ever valvuloplasty catheter that maintains the figure-8 shape throughout inflation, which allows for leaflet hyper-extension to create maximum valve area opening, without increasing the risk of overstretching the annulus. The product received 510(k) clearance in February 2014.

Raoul Quintero, president and CEO Maquet North America said, "We're seeing our customers look to BAV and TAVR as alternatives to surgical aortic valve replacement. In particular, technology improvements, operator and team experience and continued research have resulted in increased interest and growth in transcatheter aortic valve replacement."

For more information: www.maquet.com, www.intervalveinc.com

Related Content

Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval
Technology | Balloon Catheter | August 23, 2018
W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore...
Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init